Development and characterization of morin hydrate loaded microemulsion for the management of Alzheimer’s disease
Source abstract
Abstract
The aim of this study is to prepare and characterize intranasal delivery of morin hydrate loaded microemulsion for the management of Alzheimer's diseases. After intranasal delivery, brain and blood drug concentrations were found to be higher for optimized morin hydrate loaded microemulsion as compared to plain morin hydrate. Significant (P < 0.05) reduction in assessed pharmacodynamic parameters was observed after intranasal administration of morin hydrate loaded microemulsion as compared to sham control group. Daily chronic treatment with morin loaded microemulsion till the 21st day significantly increased the memory in wistar rats with STZ-induced dementia.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Cholinesterase and Neurodegenerative Diseases · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, I.S.F. College of Pharmacy, Moga, India;
Department of Pharmacology, I.S.F. College of Pharmacy, Moga, India;
Head, Pharmacy, DMCH, Ludhiana, India
References (28)
Show source-provided references
1. 10.1016/j.colsurfb.2014.11.02210.1016/j.colsurfb.2014.11.022 ↗
2. 10.1016/S0301-0082(02)00079-510.1016/S0301-0082(02)00079-5 ↗
3. 10.1016/j.ijpharm.2011.12.02810.1016/j.ijpharm.2011.12.028 ↗
4. 10.1016/j.pbb.2006.08.00710.1016/j.pbb.2006.08.007 ↗
5. 10.1016/j.ejphar.2009.08.02710.1016/j.ejphar.2009.08.027 ↗
6. 10.1016/j.tibs.2004.08.00110.1016/j.tibs.2004.08.001 ↗
7. 10.1016/0006-2952(61)90145-910.1016/0006-2952(61)90145-9 ↗
8. 10.1016/0003-9861(59)90090-610.1016/0003-9861(59)90090-6 ↗
9. 10.1016/j.ejpb.2014.03.00410.1016/j.ejpb.2014.03.004 ↗
10. 10.1016/j.nbd.2009.07.02810.1016/j.nbd.2009.07.028 ↗
11. 10.3109/1547691X.2016.115926410.3109/1547691X.2016.1159264 ↗
12. 10.1016/j.phrs.2003.11.01710.1016/j.phrs.2003.11.017 ↗
13. 10.1016/j.nbd.2011.07.00510.1016/j.nbd.2011.07.005 ↗
14. 10.1016/0003-2697(82)90118-X10.1016/0003-2697(82)90118-X ↗
15. 10.5530/jyp.2015.3.910.5530/jyp.2015.3.9 ↗
16. Moghimipour E · Adv Pharm Bull · 2013 · 3 · 63
17. 10.1016/j.bfopcu.2013.07.00210.1016/j.bfopcu.2013.07.002 ↗
18. 10.1016/j.apsb.2014.02.00210.1016/j.apsb.2014.02.002 ↗
19. 10.1016/j.bbr.2008.10.02910.1016/j.bbr.2008.10.029 ↗
20. 10.1166/asl.2010.114910.1166/asl.2010.1149 ↗
21. Sharma D · Asian J Biomater Res · 2016 · 2 · 1
22. 10.1016/j.ejpb.2015.08.00810.1016/j.ejpb.2015.08.008 ↗
23. 10.2174/15734131179448028210.2174/157341311794480282 ↗
24. 10.1016/j.jconrel.2010.08.00410.1016/j.jconrel.2010.08.004 ↗
25. 10.2174/18722110878624167910.2174/187221108786241679 ↗
26. 10.1002/jps.2048010.1002/jps.20480 ↗
27. 10.1042/bj099066710.1042/bj0990667 ↗
28. Zhang J · Int J Nanomedicine · 2011 · 6 · 3405